Cotinga Pharmaceuticals Inc. (V:COT)
Business Focus: N/A
Oct 15, 2020 07:55 am ET
IIROC Trading Halt - COT
VANCOUVER, BC, Oct. 15, 2020 /CNW/ - The following issues have been halted by IIROC:
Nov 07, 2019 03:09 pm ET
IIROC Trading Resumption - COT
VANCOUVER, Nov. 7, 2019 /CNW/ - Trading resumes in:
Oct 07, 2019 08:12 am ET
IIROC Trading Halt - COT
VANCOUVER, Oct. 7, 2019 /CNW/ - The following issues have been halted by IIROC:
Jul 18, 2019 12:40 pm ET
Cotinga Pharmaceuticals Releases Additional Interim Data of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors
Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today that the Company has released additional...
Jun 27, 2019 12:18 pm ET
Cotinga Pharmaceuticals Doses First Patient in Third Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors
Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today that the Company has commenced dosing...
Jun 05, 2019 12:42 pm ET
Cotinga Pharmaceuticals Announces Initiation of Next Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors
Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today that the Company has initiated the third...
Jun 04, 2019 06:01 pm ET
Cotinga Pharmacueticals Announces Closing of Second Tranche of Unit Offering
Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that effective June 4, 2019 (the...
May 22, 2019 05:26 pm ET
Cotinga Pharmacueticals Announces Closing of Unit Offering
Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that effective May 22, 2019 (the...
May 08, 2019 11:10 am ET
Cotinga Pharmaceuticals Releases Early Interim Data of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors
Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today that the Company has released early...
Apr 05, 2019 01:18 pm ET
Cotinga Pharmaceuticals Reports Fiscal 2019 Third Quarter Financial and Operating Results
Cotinga Pharmaceuticals Inc. (TSX Venture: COT; OTCQB: COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, reported its financial and operating results...
Mar 19, 2019 11:00 am ET
Cotinga Pharmacueticals Provides Scientific and Business Update at Annual General Meeting and Announces Unit Offering
Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that its President & Chief Executive...
Feb 26, 2019 11:08 am ET
Cotinga Pharmaceuticals Doses First Patient in Second Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors
Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today that the Company has commenced dosing...
Jan 29, 2019 10:21 am ET
Cotinga Pharmaceuticals Doses Cohort 1 Patients With Combination Therapy in Phase 1b/2a Trial of COTI-2
Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that it has dosed the first cohort of...
Jan 15, 2019 08:00 am ET
Cotinga Pharmaceuticals Doses First Patient With Combination Therapy in Phase 1b/2a Trial of COTI-2
Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that it has dosed the first patient with...
Jan 08, 2019 12:20 pm ET
Cotinga Pharmaceuticals Enrolls Two Patients for Combination Therapy in Phase 1b/2a Trial of COTI-2
Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that it has enrolled two of three patients...
Jan 03, 2019 12:32 pm ET
Cotinga Pharmaceuticals Reports Fiscal 2019 Second Quarter Financial and Operating Results
Cotinga Pharmaceuticals Inc. (TSX Venture: COT; OTCQB: COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, reported its financial and operating results...
Nov 05, 2018 08:00 am ET
Cotinga Pharmaceuticals Announces Research Partnership with St. Vincent’s University Hospital to Evaluate COTI-2
Cotinga Pharmaceuticals Inc. (TSX Venture: COT; OTCQB: COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that it has entered into a...
Oct 02, 2018 08:00 am ET
Cotinga Pharmaceuticals Reports Fiscal 2019 First Quarter Financial and Operating Results
Cotinga Pharmaceuticals Inc. (TSX Venture: COT; OTCQB: COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, reported its financial and operating results...
Sep 19, 2018 08:00 am ET
Cotinga Pharmaceuticals Announces Presentation on COTI-2 at 11th International Symposium on Translational Research in Oncology
Cotinga Pharmaceuticals Inc. (TSX Venture: COT; OTCQB: COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that Richard Ho, M.D.,...
Aug 29, 2018 08:00 am ET
Cotinga Pharmaceuticals Reports Fiscal 2018 Fourth Quarter and Full Year Financial and Operating Results
Cotinga Pharmaceuticals Inc. (TSX Venture: COT; OTCQB: COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, reported its financial and operating results...
Jul 02, 2018 04:30 pm ET
Cotinga Pharmaceuticals Announces Management and Board Changes
Cotinga Pharmaceuticals Inc. (TSX Venture:COT) (OTCQB:COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced the appointment of Victor...
May 24, 2018 08:00 am ET
Cotinga Pharmaceuticals Announces FDA Clearance of Significant Protocol Changes for COTI-2 Clinical Program
Cotinga Pharmaceuticals Inc. (TSX-V:COT) (OTCQB:COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced the clearance of a protocol...
May 17, 2018 07:30 am ET
Cotinga Pharmaceuticals Announces Presentation on COTI-2 at the 2018 American Society of Clinical Oncology Annual Meeting
Cotinga Pharmaceuticals Inc. (TSX Venture:COT) (OTCQB:COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that the Company and its...
May 04, 2018 08:00 am ET
Cotinga Pharmaceuticals Closes $2.0M Private Placement
Cotinga Pharmaceuticals Inc. (TSX Venture:COT) (OTCQB:COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced the closing of a brokered...
Apr 03, 2018 05:00 pm ET
Cotinga Pharmaceuticals Reports Fiscal 2018 Third Quarter Financial and Operating Results
LONDON, Ontario and BOSTON, April 03, 2018 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture:COT) (OTCQB:COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, reported its financial...
Apr 03, 2018 08:00 am ET
Cotinga Pharmaceuticals Announces Presentation on COTI-2 at the American Association for Cancer Research (AACR) Annual Meeting 2018
LONDON, Ontario and BOSTON, April 03, 2018 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture:COT) (OTCQB:COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that...
Mar 20, 2018 07:00 am ET
Cotinga Pharmaceuticals Provides Update on COTI-2 Clinical Programs
Submitted regulatory package to expand ongoing Phase 1 trial to evaluate COTI-2 as a combination therapy in an expanded patient population
Mar 06, 2018 07:00 am ET
Cotinga Pharmaceuticals to Present at 30th Annual ROTH Conference
LONDON, Ontario and BOSTON, Mass., March 06, 2018 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture:COT) (OTCQB:COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced...
Jan 25, 2018 08:00 am ET
Cotinga Pharmaceuticals Announces Publication of Positive Data from Preclinical Study of COTI-2 in PLOS ONE
Cotinga Pharmaceuticals Inc. (formerly Critical Outcome Technologies Inc.) (TSX VENTURE: COT)(OTCQB: COTQF) ("Cotinga" or the "Company"), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced the publication of positive data from a preclinical study demonstrating that combining COTI-2 with commonly used chemotherapeutic agents improves efficacy and exhibits a favorable drug resistance and toxicity profile in human cancer cell lines. These results were published in PLOS ONE under the title, Novel
Jan 25, 2018 07:58 am ET
Cotinga Pharmaceuticals Announces Publication of Positive Data from Preclinical Study of COTI-2 in PLOS ONE
Cotinga Pharmaceuticals Inc. (formerly Critical Outcome Technologies Inc.) (TSX VENTURE:COT)(OTCQB:COTQF) ("Cotinga" or the "Company"), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of...
Jan 08, 2018 07:00 am ET
Critical Outcome Technologies Changes Name to Cotinga Pharmaceuticals
Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company"), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced a name change from "Critical Outcome Technologies Inc." to "Cotinga Pharmaceuticals Inc." The effective date of the name change, approved by shareholders in December 2017, is expected to be January 10, 2018.
Jan 08, 2018 06:58 am ET
Critical Outcome Technologies Changes Name to Cotinga Pharmaceuticals
Critical Outcome Technologies Inc. (TSX VENTURE:COT)(OTCQB:COTQF) ("COTI" or the "Company"), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced a name change from "Critical...
Dec 29, 2017 05:00 pm ET
Critical Outcome Technologies Reports Fiscal 2018 Second Quarter Financial and Operating Results
Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company") reported its financial and operating results today for the three- and six-month periods ended October 31, 2017. Recent highlights include:
Dec 29, 2017 04:58 pm ET
Critical Outcome Technologies Reports Fiscal 2018 Second Quarter Financial and Operating Results
Critical Outcome Technologies Inc. (TSX VENTURE:COT)(OTCQB:COTQF) ("COTI" or the "Company") reported its financial and operating results today for the three- and six-month periods ended October 31, 2017. Recent highlights include:...
Dec 28, 2017 07:00 am ET
Critical Outcome Technologies Awards Stock Options
Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE: COT)(OTCQB: COTQF), announced today that 346,428 stock options were awarded to directors under the Company's Stock Option Plan on December 20, 2017. The options have a five year life with 25% vesting at the end of each quarter during the first year following the grant date. The exercise price is $1.20 and represents the closing price of the Company's common shares on the TSX Venture Exchange on December 19, 2017, the last trading day prior to the award date.
Dec 28, 2017 06:57 am ET
Critical Outcome Technologies Awards Stock Options
Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE:COT)(OTCQB:COTQF), announced today that 346,428 stock options were awarded to directors under the Company's Stock Option Plan on December 20, 2017. The options have a...
Dec 21, 2017 07:00 am ET
Critical Outcome Technologies Provides Scientific and Business Update at Annual General Meeting and Announces Approval of Name Change
Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that its President & Chief Executive Officer, Alison Silva, presented a business and scientific update summarizing recent achievements, upcoming milestones and 2018 objectives at the Company's Annual General and Special Meeting of Shareholders ("AGM") held on Wednesday, December 20, 2017.
Dec 21, 2017 06:58 am ET
Critical Outcome Technologies Provides Scientific and Business Update at Annual General Meeting and Announces Approval of Name Change
Critical Outcome Technologies Inc. (TSX VENTURE:COT)(OTCQB:COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that its President...
Dec 19, 2017 07:00 am ET
Critical Outcome Technologies Announces Pharmacodynamic Data and Positive Signals of Efficacy from Phase 1 Dose Escalation Portion of COTI-2 Trial in Gynecological Malignancies
Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced pharmacodynamic (PD) data and positive signals of efficacy from the dose-escalation portion of its Phase 1 trial of COTI-2 in gynecological malignancies that support the continued development of COTI-2 as a potential treatment for patients.
Dec 19, 2017 06:57 am ET
Critical Outcome Technologies Announces Pharmacodynamic Data and Positive Signals of Efficacy from Phase 1 Dose Escalation Portion of COTI-2 Trial in Gynecological Malignancies
Critical Outcome Technologies Inc. (TSX VENTURE:COT)(OTCQB:COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced pharmacodynamic (PD)...
Dec 06, 2017 05:45 pm ET
Critical Outcome Technologies Annual and Special Meeting of Shareholders Rescheduled
Critical Outcome Technologies Inc. (TSX VENTURE:COT)(OTCQB:COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced a change in the...
Dec 06, 2017 05:45 pm ET
Critical Outcome Technologies Annual and Special Meeting of Shareholders Rescheduled
Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced a change in the previously set date for the Company's Annual and Special Meeting of Shareholders (the "Meeting"), which was originally scheduled for Thursday, December 7, 2017 at 9:30 a.m. Eastern Standard Time.
Nov 15, 2017 07:00 am ET
Critical Outcome Technologies Announces Pharmacokinetic Data From Phase 1 Dose Escalation Portion of COTI-2 Trial in Gynecological Malignancies
Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced pharmacokinetic (PK) data from the dose-escalation portion of its Phase 1 trial of COTI-2 in gynecological malignancies that support the continued development of COTI-2 as a potential treatment for patients.
Nov 15, 2017 06:58 am ET
Critical Outcome Technologies Announces Pharmacokinetic Data From Phase 1 Dose Escalation Portion of COTI-2 Trial in Gynecological Malignancies
Critical Outcome Technologies Inc. (TSX VENTURE:COT)(OTCQB:COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced pharmacokinetic (PK) data...
Oct 18, 2017 07:00 am ET
Critical Outcome Technologies Closes Second Tranche of $2 Million Private Placement
Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced the closing of the second tranche of a $2 million non-brokered private placement announced September 20, 2017. In the second tranche, the Company issued 482,686 units (the "Units") at a price of CAD $1.16 per Unit, for additional gross proceeds of approximately CAD $560,000 and aggregate gross proceeds of CAD $2,054,504. COTI plans to use
Oct 18, 2017 06:58 am ET
Critical Outcome Technologies Closes Second Tranche of $2 Million Private Placement
Critical Outcome Technologies Inc. (TSX VENTURE:COT)(OTCQB:COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced the closing of the second...
Oct 11, 2017 07:00 am ET
Critical Outcome Technologies Announces First Patient Dosed in Phase 1 Trial of COTI-2 in Head and Neck Squamous Cell Carcinoma
Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that the first patient was dosed in the head and neck squamous cell carcinoma (HNSCC) arm of its Phase 1 trial of COTI-2 at a dosage level of 1.0 mg/kg.
Oct 11, 2017 06:58 am ET
Critical Outcome Technologies Announces First Patient Dosed in Phase 1 Trial of COTI-2 in Head and Neck Squamous Cell Carcinoma
Critical Outcome Technologies Inc. (TSX VENTURE:COT)(OTCQB:COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that the first...
Sep 29, 2017 05:57 pm ET
Critical Outcome Technologies Reports Fiscal 2018 First Quarter Financial and Operating Results
Critical Outcome Technologies Inc. (TSX VENTURE:COT)(OTCQB:COTQF) ("COTI" or the "Company") reported its financial and operating results today for the three-month period ended July 31, 2017. Recent highlights include:
Progressed...
Sep 29, 2017 05:57 pm ET
Critical Outcome Technologies Reports Fiscal 2018 First Quarter Financial and Operating Results
Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company") reported its financial and operating results today for the three-month period ended July 31, 2017. Recent highlights include:
Sep 20, 2017 07:00 am ET
Critical Outcome Technologies Closes $1.5 Million Private Placement
Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that it closed the first tranche of a non-brokered private placement with accredited investors primarily from its existing investor base. The Company issued approximately 1,300,000 units (the "Units") at a price of CAD $1.16 per Unit, for gross proceeds of approximately $1,500,000. Additional funding is expected from an upcoming second
Sep 20, 2017 06:58 am ET
Critical Outcome Technologies Closes $1.5 Million Private Placement
Critical Outcome Technologies Inc. (TSX VENTURE:COT)(OTCQB:COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that it closed the first...
Sep 07, 2017 08:00 am ET
Critical Outcome Technologies Announces CEO to Co-chair Global Genes Rare Partnering & Investor Forum
Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that Alison Silva, President and Chief Executive Officer, will co-chair the Global Genes RARE Partnering & Investor Forum on Thursday, September 14, 2017 in Irvine, CA.
Sep 07, 2017 07:58 am ET
Critical Outcome Technologies Announces CEO to Co-chair Global Genes Rare Partnering & Investor Forum
Critical Outcome Technologies Inc. (TSX VENTURE:COT)(OTCQB: COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that Alison Silva,...
Sep 05, 2017 08:00 am ET
Critical Outcome Technologies to Present at Rodman & Renshaw 19th Annual Global Investment Conference
Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that Dr. Richard Ho, Chief Scientific Officer, will present at the Rodman & Renshaw 19th Annual Global Investment Conference on Tuesday, September 12, 2017 at 3:50 P.M. ET in New York, NY. Dr. Ho will provide a Company update during the presentation and, together with Alison Silva, President & CEO, will be available to participate in
Sep 05, 2017 07:58 am ET
Critical Outcome Technologies to Present at Rodman & Renshaw 19th Annual Global Investment Conference
Critical Outcome Technologies Inc. (TSX VENTURE:COT)(OTCQB:COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that Dr. Richard Ho,...
Aug 28, 2017 08:30 am ET
Critical Outcome Technologies Announces Fourth Quarter and Full Year 2017 Financial Results
Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, reported its financial and operating results today for the fourth quarter and the fiscal year ended April 30, 2017 ("FYE 2017").
Aug 28, 2017 08:28 am ET
Critical Outcome Technologies Announces Fourth Quarter and Full Year 2017 Financial Results
Critical Outcome Technologies Inc. (TSX VENTURE:COT)(OTCQB:COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, reported its financial and...
Aug 14, 2017 08:00 am ET
Critical Outcome Technologies Completes Phase 1 Dose Escalation Portion of COTI-2 Trial in Gynecological Malignancies
Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that it has completed the dose escalation portion of its Phase 1 study of COTI-2 in women with advanced gynecologic cancers who have failed conventional therapy. In addition, COTI announced that it has initiated an expansion arm of its Phase 1 study in patients with head and neck squamous cell carcinoma (HNSCC). The Dose Escalation Committee (DEC),
Aug 14, 2017 07:58 am ET
Critical Outcome Technologies Completes Phase 1 Dose Escalation Portion of COTI-2 Trial in Gynecological Malignancies
Critical Outcome Technologies Inc. (TSX VENTURE:COT)(OTCQB:COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that it has completed the...
Jun 28, 2017 09:15 am ET
Critical Outcome Technologies Addresses Recent Trading Activity
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company") announces, in response to the recent trading activity in its stock, that it has no material changes to report at this time. The Company believes the...
Jun 23, 2017 08:30 am ET
Critical Outcome Technologies Announces Share Consolidation
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that in accordance...
May 11, 2017 08:30 am ET
Critical Outcome Technologies Appoints Experienced Biotech Leader as Chief Scientific Officer
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that Richard Ho, M.D.,...
Mar 17, 2017 08:30 am ET
Critical Outcome Technologies Announces CEO to Moderate Rare Diseases Panel at BIO-Europe
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company") announced today that Alison Silva, President and CEO, will be moderating a panel discussion entitled "The Business of Rare Disease Company Development"...
Mar 16, 2017 08:30 am ET
Critical Outcome Technologies Reports Third Quarter Financial and Operating Results for Fiscal Year 2017
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company") reported its financial and operating results today for the three- and nine-month periods ended January 31, 2017. Major highlights for the quarter...
Feb 01, 2017 08:30 am ET
Critical Outcome Technologies Announces Departure of Chief Scientific Officer
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today that Dr. Wayne Danter...
Jan 17, 2017 08:30 am ET
Critical Outcome Technologies to Be a Panelist and Presenter at Cantech Investment Conference in Toronto
Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company") a clinical stage biotechnology company advancing a pipeline of targeted therapies for the treatment of cancer, announced today that it will be a panelist...
Jan 10, 2017 08:30 am ET
Critical Outcome Advances to Fourth Cohort in Phase 1 Study of COTI-2 in Gynecologic Cancers
Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE: COT) (OTCQB: COTQF), a clinical stage biotechnology company advancing a pipeline of targeted therapies for the treatment of cancer, announced today that the Company has...
Jan 03, 2017 08:30 am ET
Critical Outcome Technologies Awards Stock Options
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company") announced today that an aggregate of 1,800,000 common share options were awarded to senior management of the Company."The Board believes in the importance...
Dec 19, 2016 08:50 am ET
Critical Outcome Technologies Reports Second Quarter Financial and Operating Results for Fiscal 2017
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company") reported its financial and operating results today for the three and six month periods ended October 31, 2016. Major highlights for the quarter...
Dec 08, 2016 08:30 am ET
Critical Outcome Technologies Appoints Alison Silva as Chief Executive Officer
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today that its Board of...
Oct 17, 2016 08:30 am ET
Critical Outcome Technologies Awards Stock Options
Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE: COT) (OTCQB: COTQF), announced today that 1,691,427 stock options were awarded to directors and employees under the Company's Stock Option Plan on October 13, 2016. The award...
Oct 14, 2016 08:46 am ET
Critical Outcome Technologies Provides Update on Recent Achievements and Future Strategic Objectives at Annual General Meeting
Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE: COT) (OTCQB: COTQF), announced today that its Chief Executive Officer, Dr. Wayne Danter, and President, Ms. Alison Silva, provided a summary of the key milestones achieved...
Oct 11, 2016 09:21 am ET
Critical Outcome Technologies Announces Next Clinical Candidate, COTI-219, Targeting KRAS
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company") a clinical-stage biopharmaceutical company advancing innovative and targeted therapies for the treatment of cancer, announced today that it has declared...
Sep 29, 2016 08:30 am ET
Critical Outcome Technologies Reports Fiscal 2017 First Quarter Financial and Operating Results
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company") reported its financial and operating results today for the three-month period ended July 31, 2016. Major highlights for the quarter included:Commencing...
Sep 13, 2016 08:30 am ET
Critical Outcome Appoints Dr. Bharatt Chowrira to Its Board of Directors
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company") a clinical-stage biopharmaceutical company advancing innovative and targeted therapies for the treatment of cancer, announced today that it has appointed...
Aug 23, 2016 08:30 am ET
Critical Outcome Technologies Announces the Opening of Its U.S. Headquarters
Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company") a clinical-stage biopharmaceutical company advancing innovative and targeted therapies for the treatment of cancer, announced the official opening of its...
Aug 03, 2016 07:30 am ET
Critical Outcome Technologies Reports Year-End Financial & Operating Results
Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE: COT) (OTCQB: COTQF), a clinical-stage biopharmaceutical company advancing innovative and targeted therapies for the treatment of cancer, reported its financial and operating...
Jul 12, 2016 09:17 am ET
Critical Outcome Initiates Third Cohort in Phase 1 Study of COTI-2 in Gynecologic Cancers
Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE: COT) (OTCQB: COTQF), announced today that the Company has commenced dosing women in the third cohort of its ongoing Phase 1 clinical trial of COTI-2 intended for the...
Jul 06, 2016 08:30 am ET
Critical Outcome Technologies Awards Stock Options
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company") announced today that 3,000,000 stock options were awarded to certain executive officers on July 5, 2016. "We made substantial progress during fiscal 2016...
Jun 15, 2016 09:15 am ET
Critical Outcome Technologies Appoints Experienced Industry Executive as New President
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today the appointment of Ms....
Jun 08, 2016 07:05 pm ET
Critical Outcome Announces No Material Change
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company") is issuing this press release in response to a request by the Investment Industry Regulatory Organization of Canada ("IIROC") to comment on recent trading...
Jun 06, 2016 08:30 am ET
Critical Outcome Activates Second Clinical Trial Site for Its COTI-2 Gynecological Cancer Study
Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company") announced today the opening on June 3, 2016, of a second treatment site in its Phase 1 clinical trial of COTI-2 for gynecological cancers. This site, at...
Jun 03, 2016 09:07 am ET
Critical Outcome Technologies Receives $1.6M From Warrant Exercises
Critical Outcome Technologies Inc.
(TSX VENTURE: COT)
(OTCQB: COTQF)
("COTI" or the "Company") announced today that all the common share purchase warrants and compensation warrants issued in a private placement financing that closed...
Jun 01, 2016 08:30 am ET
Critical Outcome to Present at International Li-Fraumeni Syndrome Conference and at BIO International Convention
Critical Outcome Technologies Inc.
(TSX VENTURE: COT)
(OTCQB: COTQF)
("COTI" or the "Company") announced today that the Company has been invited to present at the upcoming International Li-Fraumeni Syndrome ("LFS") Conference in...
May 24, 2016 08:30 am ET
Critical Outcome Receives Additional Patent Protection for Potential Transformational P53 Cancer Treatment
Critical Outcome Technologies Inc.
(TSX VENTURE: COT)
(OTCQB: COTQF)
("COTI" or the "Company") announced today that it has recently been granted two additional patents that further protect the mechanism of action and treatment of...
Apr 27, 2016 08:00 am ET
Critical Outcome Technologies Augments Advisory Board Drug Development Experience
Critical Outcome Technologies Inc.
(TSX VENTURE: COT)
(OTCQB: COTQF)
("COTI" or the "Company") announced today the addition of Dr. Nancy Chang to its Scientific Advisory Board to support the Company in the clinical development of its...
Apr 19, 2016 08:30 am ET
Critical Outcome Commences Treatment of Second Cohort in Phase 1 Study of COTI-2 in Gynecologic Cancers
Critical Outcome Technologies Inc. ("COTI" or the "Company")
(TSX VENTURE: COT)
(OTCQB: COTQF), announced today that the Company commenced treating patients in the second cohort of its ongoing Phase 1 clinical trial of COTI-2 for the...
Mar 30, 2016 08:15 am ET
Critical Outcome Technologies Completes Private Placement With a Successful U.S. Life Science Investor
This news release is intended for distribution in Canada only and is not intended for distribution to United States newswire services or dissemination in the United States.
Critical Outcome Technologies Inc.
(TSX VENTURE: COT)...
Mar 22, 2016 02:41 pm ET
Critical Outcome Technologies Provides Market Update
Critical Outcome Technologies Inc.
(TSX VENTURE: COT)
(OTCQB: COTQF)
("COTI" or the "Company") announced at the request of IIROC that its continuous disclosure responsibilities are up to date and all material transactions and news in...
Mar 17, 2016 08:30 am ET
Critical Outcome Technologies Announces Funding Received Through Warrant Exercises
Critical Outcome Technologies Inc.
(TSX VENTURE: COT)
(OTCQB: COTQF)
("COTI" or the "Company") announced today that it realized gross proceeds of $1,447,125 upon the exercise of 4,823,750 common share purchase warrants that would...
Mar 14, 2016 09:13 am ET
Critical Outcome Launches Rosalind -- A Precision Medicine Platform Designed to Provide Cancer Treatment Options
Critical Outcome Technologies Inc. ("COTI" or the "Company")
(TSX VENTURE: COT)
(OTCQB: COTQF), announced today the launch of ROSALIND™, a smart data platform designed to provide personalized drug treatment options for cancer patients...
Mar 11, 2016 04:05 pm ET
Critical Outcome Technologies Reports Fiscal 2016 Third Quarter Financial and Operating Results
Critical Outcome Technologies Inc.
(TSX VENTURE: COT)
(OTCQB: COTQF)
("COTI" or the "Company") reported its financial and operating results today for the three and nine month periods ended January 31, 2016.The most notable event in...
Feb 16, 2016 08:30 am ET
Critical Outcome Treats First Patient in Phase 1 Study of COTI-2 in Gynecologic Cancers
Critical Outcome Technologies Inc. ("COTI" or the "Company")
(TSX VENTURE: COT)
(OTCQB: COTQF), announced today that the first patient in the Company's Phase 1 clinical trial of COTI-2 for the treatment of gynecological cancers has...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
